Contraception (Birth Control) and Family Planning PubHealthInfo

[PubHealth.info Homepage] [Category Homepage] [Disclaimer/Copyrights] [Feedback]

Thank you for your kind visit to PubHealth.info®, an information portal created in technical collaboration with PakMed Biomedical Solutions * * * PubHealth.info® presents hundreds of thousands of informative Web pages on a variety of public health issues / issues * * * An ultimate source of information for teachers, students and research workers who need to find information on various public health issues, like population planning, contraception, HIV AIDS, STDs, maternal and child health, communicable and non-communicable disease, etc. * * * PubHealth.info® regularly updates the repository of these hundreds of thousands of informative Web pages * * * PubHealth.info® is one of the world's largest repositories and information portals with online Web pages on public health issues particularly those pertaining to developing countries!

PubHealth.info® (a subsidiary of PakMed) presents scientific information mainly based on abstracts of articles published on a variety of public health issues/topics, particularly encompassing population planning, disease prevention, maternal and child health, and communicable and non-communicable diseases (like HIV AIDS, malaria, etc) that are affecting a significant portion of population in developing and developed countries. Here you can find abstracts of articles published on a variety of public health topics under category "Contraception (Birth Control) and Family Planning". Contraception (birth control) is a regimen of one or more actions, devices, or medications followed in order to deliberately prevent or reduce the likelihood of a woman becoming pregnant or giving birth. Therefore contraception is the utilization of various and sundry surgical procedures, devices, practices, agents, or drugs with the intention of preventing conception or impregnation (pregnancy). Methods and intentions typically termed birth control may be considered a pivotal ingredient to family planning. Birth control is a controversial political and ethical issue in many cultures and religions, and although it is generally less controversial than abortion specifically.

YEAR: 2004

CATEGORY: Contraception (Birth Control) and Family Planning

TITLE

The contraceptive vaginal ring (NuvaRing) hemostasis: a comparative study.

AUTHORS

Magnusdóttir EM; Bjarnadóttir RI; Önundarson PT; Gudmundsdóttir BR;

SOURCE

Contraception. 2004 Jun;69(6):461-467.

ABSTRACT

This open-label, nonrandomized study compared changes in hemostatic variables during NuvaRing and oral

levonorgestrel 150 µg/ethinylestradiol 30 µg (LNG/EE) use for six cycles. Eighty-seven women started the study, 44

with NuvaRing and 43 with the LNG/EE oral contraceptive. For most procoagulation variables, there was no difference

between NuvaRing and oral LNG/EE; only Factor VII levels increased in the NuvaRing group and decreased in the

LNG/EE group. The majority of assessed variables show that anticoagulation and fibrinolytic activity was comparable

between the NuvaRing and oral LNG/EE groups. Antithrombin activity and protein C activity both tended to be higher

with NuvaRing. Levels of tissue plasminogen activator decreased in both groups but the reduction was smaller with

NuvaRing. There were no significant differences in fibrin turnover between the treatment groups. The data show that

both NuvaRing and oral LNG/EE are associated with a minimal effect on hemostatic variables. (PubHealth.info

Document ID: CONT1T 515-06)

PubHealth.info NOTE: The author(s) of this article titled, "The contraceptive vaginal ring (NuvaRing) hemostasis: a

comparative study.", is(are) Magnusdóttir EM; Bjarnadóttir RI; Önundarson PT; Gudmundsdóttir BR; Geirsson RT.

The source of this article is "Contraception. 2004 Jun;69(6):461-467.". This article was published in 2004 in English

language(s). (PubHealth.info® Document ID: CONT1T 515-06. All rights reserved with PubHealth.info) PIN: 515

This article is peer-reviewed.

This page is optimized to be viewed by Java script enabled Microsoft® Internet Explorer 6 or later version, at screen resolution of 800 by 600 pixels.